Display options
Cite
Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases. 2021;9(21):5769-5781doi: 10.12998/wjcc.v9.i21.5769.
Shih, C. A., & Chen, W. C. (2021). Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World journal of clinical cases, 9(21), 5769-5781. https://doi.org/10.12998/wjcc.v9.i21.5769
Shih, Chih-An, and Chen, Wen-Chi. "Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy." World journal of clinical cases vol. 9,21 (2021): 5769-5781. doi: https://doi.org/10.12998/wjcc.v9.i21.5769
Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases. 2021 Jul 26;9(21):5769-5781. doi: 10.12998/wjcc.v9.i21.5769. PMID: 34368296; PMCID: PMC8316946.
Copy Download .nbib Format: NLM
Share it on

World J Clin Cases. 2021 Jul 26;9(21):5769-5781. doi: 10.12998/wjcc.v9.i21.5769.

Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy.

World journal of clinical cases

Chih-An Shih, Wen-Chi Chen

Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.

PMID: 34368296 PMCID: PMC8316946 DOI: 10.12998/wjcc.v9.i21.5769

Abstract

Hepatitis B virus (HBV) reactivation can lead to severe acute hepatic failure and death in patients with HBV infection. HBV reactivation (HBVr) most commonly develops in patients undergoing cancer chemotherapy, especially B cell-depleting agent therapy such as rituximab and ofatumumab for hematological or solid organ malignancies and that receiving hematopoietic stem cell transplantation without antiviral prophylaxis. In addition, the potential consequences of HBVr is particularly a concern when patients are exposed to either immunosuppressive or biologic therapies for the management of rheumatologic diseases, inflammatory bowel disease and dermatologic diseases. Thus, screening with HBV serological markers and prophylactic or pre-emptive antiviral treatment with nucleos(t)ide analogues should be considered in these patients to diminish the risk of HBVr. This review discusses the clinical manifestation, prognosis and management of HBVr, risk stratifications of cancer chemotherapy and immunosuppressive therapy and international guideline recommendations for the prevention of HBVr in patients with HBV infection and resolved hepatitis B.

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Keywords: Chemotherapy; Hepatitis B virus; Immunosuppression; Prevention; Reactivation

Conflict of interest statement

Conflict-of-interest statement: The authors declare having no conflict of interest.

References

  1. Bone Marrow Transplant. 2003 Feb;31(4):295-300 - PubMed
  2. Clin Liver Dis. 2020 Aug;24(3):317-333 - PubMed
  3. J Clin Oncol. 1999 Jan;17(1):394-8 - PubMed
  4. Liver Int. 2015 Nov;35(11):2363-9 - PubMed
  5. N Engl J Med. 1997 Dec 11;337(24):1733-45 - PubMed
  6. J Infect Dis. 2017 Nov 16;216(suppl_8):S778-S784 - PubMed
  7. Hepatol Int. 2016 Jan;10(1):1-98 - PubMed
  8. Gastroenterology. 2008 Oct;135(4):1192-9 - PubMed
  9. PLoS One. 2015 Aug 14;10(8):e0132426 - PubMed
  10. Bone Marrow Transplant. 1997 Apr;19(8):795-9 - PubMed
  11. J Clin Oncol. 2015 Jul 1;33(19):2212-20 - PubMed
  12. J Med Virol. 2016 Sep;88(9):1576-86 - PubMed
  13. Hepatology. 2009 Sep;50(3):661-2 - PubMed
  14. Liver Int. 2004 Dec;24(6):540-6 - PubMed
  15. Ann Gastroenterol. 2018 Jul-Aug;31(4):480-490 - PubMed
  16. Hepatology. 2008 Mar;47(3):844-53 - PubMed
  17. Blood Rev. 2013 May;27(3):155-64 - PubMed
  18. Hepatology. 2009 May;49(5 Suppl):S1-3 - PubMed
  19. Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7 - PubMed
  20. J Med Virol. 2003 Aug;70(4):553-61 - PubMed
  21. J Clin Exp Hepatol. 2018 Dec;8(4):403-431 - PubMed
  22. Gastroenterology. 2015 Jan;148(1):221-244.e3 - PubMed
  23. Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):209-19 - PubMed
  24. Br J Cancer. 2004 Apr 5;90(7):1306-11 - PubMed
  25. J Oncol Pract. 2012 Jul;8(4):e32-9 - PubMed
  26. PLoS One. 2017 Sep 12;12(9):e0184550 - PubMed
  27. Br J Haematol. 2007 Mar;136(5):699-712 - PubMed
  28. Mod Rheumatol. 2011 Feb;21(1):16-23 - PubMed
  29. Ann Oncol. 2011 May;22(5):1170-1180 - PubMed
  30. Lancet. 2009 Feb 14;373(9663):582-92 - PubMed
  31. Hepatology. 2015 Aug;62(2):387-96 - PubMed
  32. Chemotherapy. 2009;55(2):69-75 - PubMed
  33. Hepatology. 2015 Feb;61(2):703-11 - PubMed
  34. Eur J Clin Pharmacol. 2018 Sep;74(9):1111-1119 - PubMed
  35. Ann Oncol. 2012 Feb;23(2):421-6 - PubMed
  36. Ann Intern Med. 2016 Jan 5;164(1):30-40 - PubMed
  37. Hepatology. 2014 Jun;59(6):2092-100 - PubMed
  38. PLoS One. 2015 Jun 29;10(6):e0131545 - PubMed
  39. J Hepatol. 2004 Sep;41(3):427-35 - PubMed
  40. Blood. 2019 Jan 10;133(2):137-146 - PubMed
  41. Ann Intern Med. 2008 Apr 1;148(7):519-28 - PubMed
  42. J Clin Oncol. 2013 Aug 1;31(22):2765-72 - PubMed
  43. Clin Med (Lond). 2018 Jun;18(3):212-218 - PubMed
  44. Cancer. 2010 Oct 15;116(20):4769-76 - PubMed
  45. Curr Oncol. 2010 Nov;17(6):32-8 - PubMed
  46. PLoS One. 2015 Apr 15;10(4):e0120749 - PubMed
  47. Int J Rheum Dis. 2013 Oct;16(5):527-31 - PubMed
  48. Biol Blood Marrow Transplant. 2009 Sep;15(9):1049-59 - PubMed
  49. World J Gastroenterol. 2016 Jul 28;22(28):6484-500 - PubMed
  50. Hepatology. 2009 May;49(5 Suppl):S156-65 - PubMed
  51. Oncotarget. 2016 May 24;7(21):30642-58 - PubMed
  52. J Med Virol. 2000 Nov;62(3):299-307 - PubMed
  53. Clin Adv Hematol Oncol. 2012 Jun;10(6):370-8 - PubMed
  54. Aliment Pharmacol Ther. 2006 Oct 1;24(7):1003-16 - PubMed
  55. J Gastroenterol Hepatol. 2004 Sep;19(9):958-69 - PubMed
  56. J Crohns Colitis. 2014 Nov;8(11):1529-38 - PubMed
  57. World J Hepatol. 2015 May 8;7(7):954-67 - PubMed
  58. Leuk Lymphoma. 2015 Jun;56(6):1710-7 - PubMed
  59. World J Gastroenterol. 2013 Feb 14;19(6):923-30 - PubMed
  60. Gut. 2004 Sep;53(9):1363-5 - PubMed
  61. Gut. 2010 Oct;59(10):1340-6 - PubMed
  62. Gastroenterology. 2017 May;152(6):1297-1309 - PubMed
  63. Gastroenterology. 1991 Jan;100(1):182-8 - PubMed
  64. Hepatology. 2018 Apr;67(4):1560-1599 - PubMed
  65. PLoS One. 2015 Apr 20;10(3):e0122041 - PubMed
  66. Br J Cancer. 2013 May 28;108(10):1931-5 - PubMed
  67. Br J Cancer. 2011 Feb 15;104(4):559-63 - PubMed
  68. World J Gastroenterol. 2014 Jun 28;20(24):7675-85 - PubMed
  69. World J Gastroenterol. 2019 Jul 14;25(26):3299-3312 - PubMed
  70. Semin Liver Dis. 2013 May;33(2):167-77 - PubMed
  71. J Hepatol. 2017 Aug;67(2):370-398 - PubMed
  72. JAMA. 2014 Dec 17;312(23):2521-30 - PubMed
  73. J Clin Oncol. 2014 Nov 20;32(33):3736-43 - PubMed
  74. Support Care Cancer. 2012 Nov;20(11):2999-3008 - PubMed
  75. Blood Transfus. 2019 Nov;17(6):403-408 - PubMed

Publication Types